Educational research resource. Contains sponsored placement — see editorial disclosure.

Mechanism

Lipolysis vs lipogenesis (lipolytic peptide fragments)

Some research peptides claim to push fat tissue toward burning stored fat rather than storing more. In humans, the evidence base for these fragments has not matured into licensed medicines and clinical effect sizes have not been established with rigour.

By Metabolic Peptides Editorial TeamReviewed by Scientific Review PanelLast updated

Plain-English explanation

Some research peptides claim to push fat tissue toward burning stored fat rather than storing more. In humans, the evidence base for these fragments has not matured into licensed medicines and clinical effect sizes have not been established with rigour.

Research-level explanation

Preclinical-heavy. Limited and largely older human data. None of these fragments are licensed for human therapeutic use.

Common misconceptions

Common claimMore accurate framing
Lipolytic fragments are a clinically established weight-loss tool.There is no UK or EU licensed therapeutic indication for AOD-9604 or HGH Fragment 176-191. Trial data are limited and the molecules are research-only.

Safety relevance

Research-only — human safety evidence is limited and dependent on small studies of variable quality.

What this mechanism does not prove
  • Preclinical lipolysis data do not equal clinical body-weight or cardiometabolic outcome benefit.

Related peptide profiles

Related trials

No published trials yet linked to this page. Source verification required.

Related conditions

Source quality

Sources are tagged by class. Regulatory documents, peer-reviewed publications and trial registry records are preferred. Manufacturer disclosures and conference material are accepted where peer-reviewed publication is not yet available; preprints are flagged.

Last reviewed 20 May 2026 · Lipolysis vs lipogenesis (lipolytic peptide fragments) mechanism · Metabolic Peptides editorial team